MARKET

LXRX

LXRX

Lexicon Pharmaceuticals Inc
NASDAQ
2.640
+0.090
+3.53%
After Hours: 2.670 +0.03 +1.14% 16:36 06/29 EDT
OPEN
2.550
PREV CLOSE
2.550
HIGH
2.670
LOW
2.485
VOLUME
4.62M
TURNOVER
--
52 WEEK HIGH
2.670
52 WEEK LOW
0.8006
MARKET CAP
1.17B
P/E (TTM)
-36.9231
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LXRX last week (0622-0626)?
Weekly Report · 11h ago
Health Care had the best week vs. the S&P 500 on record
Seeking Alpha · 2d ago
Weekly Report: what happened at LXRX last week (0615-0619)?
Weekly Report · 06/22 09:37
Weekly Report: what happened at LXRX last week (0608-0612)?
Weekly Report · 06/15 09:37
Weekly Report: what happened at LXRX last week (0601-0605)?
Weekly Report · 06/08 09:35
Lexicon presents new sotagliflozin Type 1 diabetes subgroup analysis at ADA 2026 sessions
PUBT · 06/03 12:05
Lexicon Pharmaceuticals’ Earnings Call Highlights Milestone-Fueled Surge
TipRanks · 06/02 00:10
Weekly Report: what happened at LXRX last week (0525-0529)?
Weekly Report · 06/01 09:37
More
About LXRX
Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The Company develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The Company also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders.

Webull offers Lexicon Pharmaceuticals Inc stock information, including NASDAQ: LXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LXRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LXRX stock methods without spending real money on the virtual paper trading platform.